Betta's ensartinib cuts ALK-positive NSCLC recurrence risk 80% in Phase 3
The ELEVATE trial's adjuvant ensartinib arm hit 86.4% 2-year disease-free survival versus 53.5% on placebo, and Betta says China has already accepted its marketing application.
Executive Summary
- Adjuvant ensartinib cut the two-year rate of recurrence or death by a wide margin against placebo in resected ALK-positive lung cancer, meeting the trial's primary endpoint.
- The finding moves an already-approved ALK inhibitor earlier in the treatment course, into the adjuvant setting where chemotherapy alone has offered limited benefit.
- China has already accepted the marketing application for this adjuvant use, and filings in other markets are underway, putting the sponsor ahead of the typical data-to-filing gap.
- No other ALK-directed therapy has reached late-stage testing in this specific post-surgical population, leaving ensartinib without a direct rival in this line even as multiple ALK inhibitors compete in later lines of NSCLC.
The readout
The ELEVATE trial (NCT05341583) randomized 274 patients across 56 Chinese medical centers 1:1 to oral ensartinib or placebo after complete surgical resection and any planned adjuvant chemotherapy. Two-year disease-free survival reached 86.4% on ensartinib versus 53.5% on placebo in the stage II-IIIB subgroup, with a hazard ratio of 0.20 (95% CI 0.11-0.38); a similar hazard ratio of 0.20 (95% CI 0.10-0.37) held across the full stage IB-IIIB population. The trial's registered primary endpoint was disease-free survival, with overall survival and DFS rates at 3 and 5 years as secondary measures. Betta's chairman and chief executive, Ding Lieming, called the NEJM publication "a landmark achievement showcasing Chinese clinical oncology research on the global academic stage". NCT05341583+1Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung CancerNCT05341583Groundbreaking Achievement: Study of Ensartinib as Postoperative Adjuvant Therapy Published in The New England Journal of MedicineJul 9, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the result extends
Ensartinib is not a new mechanism entering the clinic. It is a next-generation ALK inhibitor already approved in China for first- and second-line ALK-positive NSCLC and cleared in the United States in December 2024, where it was subsequently added to the NCCN guidelines. The ELEVATE result extends that approved drug into the adjuvant setting, after surgery, where standard platinum-based chemotherapy has offered only modest benefit against recurrence. The bar this readout had to clear was replication of ensartinib's established late-line activity in an earlier, curative-intent line, not proof of a new biological effect, and the disease-free survival gap over placebo met that bar with room. GroundbreakingGroundbreaking Achievement: Study of Ensartinib as Postoperative Adjuvant Therapy Published in The New England Journal of MedicineJul 9, 2026
Regulatory position
Betta says the marketing application for ensartinib's adjuvant indication has already been accepted in China, and applications in other markets, including the European Union, are progressing. That places the regulatory filing ahead of, or concurrent with, the NEJM publication rather than waiting on it, a sequence distinct from a typical readout-then-file pattern. GroundbreakingGroundbreaking Achievement: Study of Ensartinib as Postoperative Adjuvant Therapy Published in The New England Journal of MedicineJul 9, 2026
Where it sits competitively
Among industry trials matched on ALK and this stage IB-IIIB, T3N2M0-inclusive adjuvant population, ensartinib's ELEVATE study is the only one to reach Phase 3. A Chugai Pharmaceutical ALK program (NCT07617337) sits at Phase 1 with the same target and modality but a different line of therapy. Roche's adjuvant alectinib trial (NCT03456076) tests the same target and modality in a related adjuvant ALK-positive NSCLC population, completing in 2023, giving ensartinib a same-target precedent for the strategy of moving an ALK inhibitor into the post-surgical setting even though the specific staged population differs. Beyond ALK, the broader NSCLC Phase 3 field is active with KRAS, HER2, EGFR, and PD-1/PD-L1-directed programs from Merck, Roche, Boehringer Ingelheim, Bristol-Myers Squibb, and AbbVie, none of which share ensartinib's target and none of which bear directly on this adjuvant ALK-positive result.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.